AZN241115P85000
- 18.90
- -1.00-5.03%
AstraZeneca Newsroom
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
Express News | Bernstein: The target price for astrazeneca has been lowered from 20,000 pence to 18,000 pence.
AstraZeneca: Overcoming Short-term Challenges With Robust Long-term Potential
AstraZeneca Director Bolsters Stake With Share Purchase
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
The ADC therapy jointly developed by astrazeneca and Daiichi Sankyo has submitted a marketing application to the FDA.
On November 13, Gelonghui announced that astrazeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) for their jointly developed Trop2 targeted antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) based on feedback from the usa FDA, seeking accelerated approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, who have previously received systemic treatment (including EGFR targeted therapy).
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $88
Express News | AstraZeneca : BMO Cuts Target Price to $88 From $89
AlphaValue/Baader Europe Keeps AstraZeneca Rating on Portfolio Strength
MSD and AstraZeneca Report Positive Topline Data From Koselugo Trial for NF1
AstraZeneca Plans Major $3.5bn Expansion Drive in the US
Die Turacoz Group Überbrückt Die Kluft Zwischen Globalen Und Regionalen Teams Bei Der Erstellung Und Verbreitung Medizinischer Inhalte Auf Der Reuters Pharma Customer Engagement Europe 2024, London
Turacoz Group En Reuters Pharma Customer Engagement Europe 2024 (Londres)
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating
Barclays Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca Raised to Buy From Hold by Intron Health
Astrazeneca (AZN.US) submits potential blockbuster ADC therapy for FDA approval.
AstraZeneca (AZN.US) has submitted a potential blockbuster ADC therapy for FDA approval.
AstraZeneca Reports Strong Growth in Q3 2024
Astrazeneca (AZN.US) and Merck (MRK.US) jointly announced the positive top-line results of the KOMET phase 3 clinical trial.
Today, Astrazeneca (AZN.US) and Merck (MRK.US) jointly announced the positive top-line results of the phase 3 KOMET clinical trial.
Express News | AstraZeneca CEO: Not familiar with the details of the investigation of senior executives in China, will continue to invest in China.